In conclusion, we illustrated that CEMIP was highly expressed in various kinds of carcinomas, including BC, especially advanced subtypes, and predicted less favorable prognosis (negatively associated with OS, RFS, DFS, and DMFS) in BC patients, and the higher the expression of it, the worse the outcomes BC patients have. Here, CEMIP is linked to breast cancer.